Mar 2, 2023 Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
Feb 23, 2023 Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023
Jan 26, 2023 Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome
Dec 12, 2022 Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS
